Clinical Trial – A Phase II Study of Ibrutinib Plus FCR – Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute is running a clinical trial to test drugs called Ibrutinib, Fludarabine, Cyclophosphamide and Rituximab to treat chronic lymphocytic leukemia. This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

The drugs are Ibrutinib, Fludarabine, Cyclophosphamide and Rituximab.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 85 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Actual Study Start Date : October 2014
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : April 2021

For enrollment please visit www.clinicaltrials.gov.

 

Leave a Reply